An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD
Sponsor: Transcend Therapeutics • ClinicalTrials.gov ID: NCT07836647
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
This study is evaluating the safety and efficacy of TSND-201 in adults with PTSD. Eligible participants will enter a 4-week Treatment Period where they will be randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, once per week. Following the Treatment Period, participants will enter an 8-week Follow-up Period.
Interventions
-
TSND-201
(Drug)
TSND-201 capsules, given orally, once a week for four consecutive weeks
-
Placebo
(Drug)
Placebo capsules, given orally, once a week for four consecutive weeks
Eligibility criteria
Conditions
Locations
- Mountain View Clinical Research — Denver, Colorado, United States
- Bradenton Research Center — Bradenton, Florida, United States
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record